{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"52.1","value":"14.3"},{"groupId":"OG001","lowerLimit":"65.8","upperLimit":"94.1","value":"83.3"},{"groupId":"OG002","lowerLimit":"34.3","upperLimit":"99.0","value":"80.0"},{"groupId":"OG003","lowerLimit":"22.2","upperLimit":"77.8","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"description":"For ALL participants, ORR was defined as percentage of participants who achieved CR or CR with only partial hematological recovery(CRi) as per NCCN criteria. CR for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets \\>100\\*10\\^9 cells/L and ANC \\>1.0\\*10\\^9 cells/L. CRi for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; partial recovery of peripheral blood counts not meeting criteria for CR. For LL participants, ORR was defined as percentage of participants who had CR or PR during or after treatment administration but prior to start of subsequent anti-cancer therapy or allogeneic hematopoietic stem cell transplant(HSCT). CR for LL: disappearance of all evidence of disease from all sites. PR for LL: decrease of \\>=50% in sum of products of diameter of lesions of up to 6 of largest dominant nodes or nodal masses with no new lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory B-cell ALL received intrathecal methotrexate (MTX) 8 milligrams (mg): 1 to less than (\\<) 2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: greater than or equal to (\\>=) 9 years on Cycle 1 Day 1 (for all participants) and Cycle 2 and later Day 1 each Cycle (for CNS negative participants); for CNS positive participants: along with MTX, hydrocortisone (HC)/cytarabine (ARA-C) was administered per local standard practice; daratumumab 16 milligrams per kilogram (mg/kg) as intravenous (IV) infusion weekly on Days 1, 8, 15 and 22 of Cycles 1 and 2 then every 2 weeks on Days 1, 15 of Cycle 3 to 6 and every 4 weeks on Day 1 of Cycle 7 and onward; vincristine 1.5 milligrams per meter square (mg/m\\^2) IV injection/infusion once weekly on Days 1, 8, 15 and 22 of Cycle 1, then every 2 weeks on Days 1 and 15 of Cycle 2 and every 4 weeks on Day 1 of Cycle 3 and onward; prednisone 40 mg/m\\^2 orally daily on Day 1 to 28 of Cycle 1 and on Day 1 to 5 of Cycle 2 onward. Participants received treatment until disease progression, unacceptable toxicity, or proceeding hematopoietic stem cell transplant after complete response (CR), whichever came first (maximum duration: 2.3 months).","id":"OG000","title":"Cohort 1: B-cell ALL (1-17 Years)"},{"description":"Participants with relapsed/refractory T-cell ALL received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: \\>=9 years on Cycle 1 Day 1 (all participants) and Cycle 1 Days 15, and 22 (CNS negative participants);for CNS positive participants, along with MTX, HC/ARA-C was administered per local standard practice; daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22 of Cycle 1; doxorubicin 60 mg/m\\^2 IV infusion once on Day 1; vincristine 1.5 mg/m\\^2 IV injection/infusion once weekly on Days 1, 8, 15 and 22 on Cycle 1; prednisone 40 mg/m\\^2 as 2 doses (20 mg/m\\^2 per dose) orally daily on Day 1 to 28 on Cycle 1; peg-asparaginase 2500 units per meter square (U/m\\^2) as intramuscular (IM) injection/IV infusion on Days 2, 16 of Cycle 1. In Cycle 2, participants received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: \\>=9 years on Cycle 2 Days 2 and 15 (CNS negative participants); MTX, HC/ARA-C was administered on Days 2 and 15 per local standard practice (CNS positive participants); daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22; MTX 5 g/m\\^2 as IV once on Day 2, cyclophosphamide IV 1 g/m\\^2 once on Day 15; cytarabine 75 mg/m\\^2 IV/subcutaneous (SC) on Day 16 to 19 and Days 23 to 26; 6-mercaptopurine 60 mg/m\\^2 orally daily on Days 15 to 28 (maximum duration: 2.9 months).","id":"OG001","title":"Cohort 2: T-Cell ALL (1-17 Years)"},{"description":"Participants with relapsed/refractory T-cell ALL in Cycle 1 received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: \\>=9 years on Cycle 1 Day 1 (all participants) and on Cycle 1 Days 15 and 22 (CNS negative participants); for CNS positive participants, along with MTX, HC/ARA-C was administered per local standard practice; daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22 of Cycle 1; doxorubicin 60 mg/m\\^2 IV once on Day 1 of Cycle 1; vincristine 1.5 mg/m\\^2 IV injection/infusion once weekly on Days 1, 8, 15 and 22 of Cycle 1; prednisone 40 mg/m\\^2 as 2 doses (20 mg/m\\^2 per dose) orally daily on Days 1 to 28 and peg-asparaginase 2500 U/m\\^2 as IM injection/IV infusion on Days 2 and 16 of Cycle 1. In Cycle 2, participants received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg:\\>=9 years on Days 2 and 15 (CNS negative participants); MTX, HC/ARA-C was administered on Days 2 and 15 per local standard practice (CNS positive participants); daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22; MTX 5 g/m\\^2 as IV once on Day 2, cyclophosphamide 1g/m\\^2 once on Day 15; cytarabine 75 mg/m\\^2 IV/SC on Days 16 to 19 and Days 23 to 26; and 6-mercaptopurine 60 mg/m\\^2 orally daily on Days 15 to 28 (maximum duration: 2.1 months).","id":"OG002","title":"Cohort 2: T-Cell ALL (18-30 Years)"},{"description":"Participants with relapsed/refractory T-cell LL in Cycle 1 received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: \\>=9 years on Cycle 1 Day 1 (all participants) and on Cycle 1 Days 15 and 22 (CNS negative participants); for CNS positive participants, along with MTX, HC/ARA-C was administered per local standard practice; daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22 of Cycle 1; doxorubicin 60 mg/m\\^2 IV once on Day 1 of Cycle 1; vincristine 1.5 mg/m\\^2 IV injection/infusion weekly on Days 1, 8, 15 and 22 of Cycle 1; prednisone 40 mg/m\\^2 as 2 doses (20 mg/m\\^2 per dose) orally daily on Days 1 to 28 and peg-asparaginase 2500 U/m\\^2 as IM injection/IV infusion on Days 2 and 16 of Cycle 1. In Cycle 2, participants received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg:\\>=9 years on Days 2 and 15 (CNS negative participants); MTX, HC/ARA-C was administered by on Days 2 and 15 per local standard practice (CNS positive participants); daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22; MTX 5 g/m\\^2 as IV once on Day 2, cyclophosphamide 1g/m\\^2 once on Day 15; cytarabine 75 mg/m\\^2 IV/SC on Days 16 to 19 and Days 23 to 26; and 6-mercaptopurine 60 mg/m\\^2 orally daily on Days 15 to 28 (maximum duration: 2.3 months).","id":"OG003","title":"Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)"}],"paramType":"NUMBER","populationDescription":"The all treated analysis set included all enrolled participants who received at least 1 dose of daratumumab.","reportingStatus":"POSTED","timeFrame":"Up to 4 years 4 months","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}